Patents by Inventor Jianzhu Chen
Jianzhu Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896619Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.Type: GrantFiled: January 8, 2021Date of Patent: February 13, 2024Assignee: Massachusetts Institute of TechnologyInventors: Jianzhu Chen, Guozhu Xie
-
Publication number: 20230313199Abstract: Disclosed are methods of increasing mitochondrial respiration to treat obesity-related diseases and conditions, such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer, such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration. Also disclosed are methods of promoting weight gain, which is achieved by a decrease in mitochondrial respiration. Also disclosed are methods of identifying compounds useful for increasing mitochondrial respiration to treat obesity-related diseases and conditions.Type: ApplicationFiled: August 31, 2021Publication date: October 5, 2023Inventors: Jianzhu Chen, Nikola Ivica, Yingzhong Li, Ting Dong
-
Publication number: 20230149460Abstract: The present disclosure relates to cytokine-induced memory-like NK cells expressing a chimeric antigen receptor polypeptide that binds to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.Type: ApplicationFiled: March 10, 2021Publication date: May 18, 2023Applicants: Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Inc.Inventors: Jianzhu Chen, Jerome Ritz, Rizwan Romee, Han Dong, Guozhu Xie, James Dongjoo Ham
-
Publication number: 20220087950Abstract: Disclosed are methods of modulating macrophage activation to treat various diseases, such as cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases. Also disclosed are methods of identifying compounds useful for modulating macrophage activation as means to treat cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases.Type: ApplicationFiled: July 21, 2021Publication date: March 24, 2022Inventors: Jianzhu Chen, Guangan Hu
-
Publication number: 20220034903Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.Type: ApplicationFiled: October 18, 2021Publication date: February 3, 2022Inventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
-
Publication number: 20210283178Abstract: The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.Type: ApplicationFiled: January 8, 2021Publication date: September 16, 2021Inventors: Jianzhu CHEN, Guozhu XIE
-
Publication number: 20190004064Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.Type: ApplicationFiled: July 11, 2018Publication date: January 3, 2019Applicants: The Schepens Eye Research Institute, Inc., Massachusetts Institute of TechnologyInventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
-
Publication number: 20150007357Abstract: The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (HSCs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human. The invention is also directed to a method of determining whether administration of an agent causes cytokine release syndrome in an individual in need thereof comprising administering the agent to a non-human mammal that has been engrafted with HSCs and administered one or more human cytokines; and determining whether the agent causes cytokine release syndrome in the non-human mammal. If the agent causes cytokine release syndrome in the non-human mammal then the agent will cause cytokine release syndrome in the human.Type: ApplicationFiled: December 5, 2012Publication date: January 1, 2015Inventors: Salim Bouguermouh, Maroun Khoury, Qingfeng Chen, Jianzhu Chen
-
Publication number: 20140147413Abstract: The present invention comprises a composition with means to inhibit an autoimmune response and methods for using this composition to treat glaucoma and optic neuropathy.Type: ApplicationFiled: February 28, 2012Publication date: May 29, 2014Inventors: Dong Feng Chen, Jianzhu Chen, Huihui Chen
-
Patent number: 8357664Abstract: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5? or 3? terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3? terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.Type: GrantFiled: October 25, 2005Date of Patent: January 22, 2013Assignees: AVI BioPharma, Inc., M.I.T.Inventors: David A. Stein, Qing Ge, Jianzhu Chen, Patrick L. Iversen, Hong M. Moulton
-
Publication number: 20120251528Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.Type: ApplicationFiled: June 28, 2010Publication date: October 4, 2012Inventors: Ilya B. Leskov, Adam C. Drake, Maroun Khoury, Jianzhu Chen, Christian Pallasch, Michael Hemann
-
Publication number: 20120157667Abstract: Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods.Type: ApplicationFiled: June 28, 2010Publication date: June 21, 2012Inventors: Qingfeng Chen, Jianzhu Chen
-
Publication number: 20110293558Abstract: The invention in some aspects relates to methods, devices and compositions for evaluating material properties, such as mechanical and rheological properties of substances, particularly biological substances, such as cells, tissues, and biological fluids. In some aspects, the invention relates to methods, devices and compositions for evaluating material properties of deformable objects, such as cells. In further aspects, the invention relates to methods, devices and compositions for diagnosing and/or characterizing disease based on material properties of biological cells.Type: ApplicationFiled: March 21, 2011Publication date: December 1, 2011Applicant: Massachusetts Institute of TechnologyInventors: Subra Suresh, Jianzhu Chen, Irene Yin-Ting Chang
-
Publication number: 20110112169Abstract: The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FC?RI? chain, the FC?RI? chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common ? chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.Type: ApplicationFiled: September 27, 2010Publication date: May 12, 2011Applicant: Massachusetts Institute of TechnologyInventors: Jianzhu Chen, Herman N. Eisen, Qing Ge
-
Publication number: 20100298214Abstract: The present invention provides compositions, systems, and methods for identifying a patient suffering from and/or susceptible to autoimmune disease who might be likely to respond to treatment with CXCL12 and/or CXCR4 antagonists. The present invention provides novel CXCL12 and/or CXCR4 antagonists, methods of identifying novel CXCL12 and/or CXCR4 antagonists, and methods involving the use of these in the treatment of autoimmune disease.Type: ApplicationFiled: August 29, 2008Publication date: November 25, 2010Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Qibin Leng, Jianzhu Chen
-
Publication number: 20100204297Abstract: The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung.Type: ApplicationFiled: March 22, 2006Publication date: August 12, 2010Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Jianzhu Chen, Qing Ge, Herman N. Eisen
-
Publication number: 20100136072Abstract: Hydrophobic polymeric coatings which can be non-covalently applied to solid surfaces such as metals, plastics, glass, polymers, textiles, and other substrates such as fabrics, gauze, bandages, tissues, and other fibers, in the same manner as paint, for example, by brushing, spraying, or dipping, to make the surfaces virucidal and bactericidal, have been developed.Type: ApplicationFiled: November 8, 2007Publication date: June 3, 2010Applicant: Massachusetts Institute of TechnologyInventors: Jayanta Haldar, Deqiang An, Luis Álvarez de Cienguegos, Jianzhu Chen, Alexander M. Klibanov
-
Publication number: 20100040645Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual art hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.Type: ApplicationFiled: March 9, 2009Publication date: February 18, 2010Inventors: Qian Huang, Joan F.L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eiser, Richard A. Young
-
Publication number: 20090124567Abstract: The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.Type: ApplicationFiled: July 3, 2008Publication date: May 14, 2009Inventors: Jianzhu Chen, Herman N. Eisen, Qing Ge
-
Publication number: 20090106852Abstract: The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.Type: ApplicationFiled: December 6, 2007Publication date: April 23, 2009Applicant: Massachusetts Institute of TechnologyInventors: Jianzhu Chen, Herman N. Eisen, Qing Ge